OrphAI Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

OrphAI Therapeutics is a private, preclinical to Phase 2 biotech founded in 2020 and headquartered in New Haven, Connecticut. The company is advancing a focused pipeline led by LAM-001, a candidate in Phase 2 for Bronchiolitis Obliterans Syndrome (BOS) and earlier stages for pulmonary hypertension-associated disorders, alongside earlier-stage oncology and neurology programs. Utilizing an AI/ML-driven discovery platform, OrphAI aims to develop life-saving drugs for niche, underserved patient populations, operating as a pre-revenue entity with a lean, experienced leadership team.

PulmonaryOncologyNeurology

Technology Platform

AI/Machine Learning platform for small molecule drug discovery and development.

Opportunities

OrphAI has a significant opportunity to address completely unmet medical needs in orphan pulmonary diseases like BOS and specific forms of PH, where regulatory incentives and premium pricing are favorable.

Success with LAM-001 in one indication could create a clear development pathway for other related conditions, maximizing the asset's value.

The AI/ML platform also presents an opportunity to generate new pipeline candidates efficiently, potentially for partnership.

Risk Factors

The company faces high clinical risk as its lead candidate has not yet proven efficacy in later-stage trials.

Financial risk is acute as a pre-revenue private company dependent on raising capital in a challenging market.

There is also competitive and commercial risk, as eventual market entry, even in niche areas, may require partnering and sharing value.

Competitive Landscape

In pulmonary hypertension, OrphAI will compete with established PH therapies (e.g., from Johnson & Johnson, United Therapeutics) and newer entrants, though its focus on PH-ILD and SAPH subsets is more specialized. In BOS, it could be a first-to-market opportunity, but other companies are investigating therapies for transplant rejection. Its AI-driven approach places it among many biotechs leveraging computational discovery, where differentiation depends on output and validation.

More companies in AI / Machine Learning →More companies in United States →